{"id":21524,"date":"2024-07-31T16:23:13","date_gmt":"2024-07-31T10:53:13","guid":{"rendered":"https:\/\/www.rootsanalysis.com\/blog\/?p=21524"},"modified":"2025-09-18T18:40:43","modified_gmt":"2025-09-18T13:10:43","slug":"oncology-biomarkers-current-landscape","status":"publish","type":"post","link":"https:\/\/www.rootsanalysis.com\/blog\/oncology-biomarkers-current-landscape\/","title":{"rendered":"Oncology Biomarkers: Current Landscape, Growth Opportunities and Future Market Outlook"},"content":{"rendered":"\n

Over the last couple of decades, the healthcare market has witnessed the entry of several advanced and effective treatment options for cancer; these include a variety of targeted therapies, immunotherapies and certain anti-cancer vaccines as well. However, clinical cancer research is still plagued by high failure rates, various drug \/ therapy-related limitations, and treatment-based adverse effects, some of which have been proven to be fatal. A prominent concern is associated with deciding the type of treatment option to be used for a specific cancer. Patients suffering from a singular type of cancer, who may be at the same stage of the disease, have been demonstrated to exhibit different molecular profiles, and thereby, may respond differently to recommended drug \/ therapy types. These challenges can be potentially addressed with the help of novel technologies such as oncology biomarkers<\/p>\n\n\n\n

In order to address this concern, pharmaceutical developers and healthcare professionals have adopted a more personalized approach to disease diagnosis and treatment. This personalized approach has also been referred to as oncology precision medicine. Over time, several molecular oncology markers have been identified and characterized, and many have been validated for use in making important treatment-related decisions.<\/p>\n\n\n\n

The role of single analyte cancer \/ oncology biomarkers, such as PD-L1, BRAF, and EGFR, has been well-established across multiple cancer indications. However, owing to the subtle differences in genomic makeup of individual patients, these biomarkers alone have been shown to be insufficient in determining how patients are likely to respond to various drug \/ therapy types. Advances in biotechnology have enabled the development of several high throughput tools, which have led to the establishment of improved biomarkers, based on genome \/ exome profiles. Novel oncology biomarkers, such as tumor mutation burden (TMB), microsatellite instability (MSI) \/ mismatch repair (MMR) deficiency, tumor infiltrating lymphocytes (TILs), Single Nucleotide Variants (SNV), Copy Number Variants (CNV) and certain others, are presently being investigated across numerous clinical studies.<\/p>\n\n\n\n

Presently, several diagnostics-focused companies have developed \/ are developing analytical tests for these biomarkers, which are intended to assist physicians in making personalized treatment-related decisions. It is worth highlighting that many big pharmaceutical players have demonstrated interest in this domain and have launched clinical research initiatives to investigate the relevance and applications of multiple novel biomarkers.<\/p>\n\n\n\n

\"Oncology<\/figure>\n\n\n\n


Testing Solutions in the Oncology Biomarkers Market<\/strong><\/p>\n\n\n\n

The current market landscape features the presence of close to 100 oncology biomarker testing solutions. The following figure presents the distribution of cancer \/ oncology biomarker testing solutions based on the profiling technologies and analytical technique used.<\/p>\n\n\n

\n
\"Oncology<\/figure>\n<\/div>\n\n\n

Want additional details on the market? Access Cancer Biomarkers Market<\/a> report by Roots Analysis<\/p>\n\n\n\n

Competitive Landscape of Companies Offering Novel Oncology Biomarkers Testing Solutions<\/strong><\/h2>\n\n\n\n

The market features the presence of 50 cancer biomarker testing solutions providers. It is worth highlighting that more than 50% of these companies are large and very large firms, indicating the presence of well-established players in this market.<\/p>\n\n\n\n

Further, majority of these companies are headquartered in North America (~70%) followed by Europe and Asia-Pacific. It is worth highlighting that big pharma companies are also providing testing solutions for the evaluation of novel oncology biomarkers. For instance, Roche<\/a> provides cancer biomarker testing solution called the Ventana MMR RxDx Panel, which aids in the assessment of the MSI biomarker.<\/p>\n\n\n\n

Clinical Trial Analysis: Close to 620 Trials are Evaluating Novel Oncology Biomarkers to Diagnose Myriad of Cancer Indications<\/strong><\/h2>\n\n\n\n

Close to 620 clinical trials have been registered across different geographical regions to evaluate various novel biomarkers for cancer detection. Majority (>40%) of these trials were registered in Europe. Further, the maximum number of patients (32,202) have been enrolled in clinical trials conducted in Europe, which account for 43% of the overall enrollment. It is worth mentioning that Merck is conducting the maximum number of trials in this industry for various cancer indications, including bladder cancer, breast cancer, colorectal cancer, gastrointestinal cancer, gynecological cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, prostate cancer and skin cancer.<\/p>\n\n\n\n

Market Trend Analysis: Increase in Article Publications Reflect the Rising Interest of Companies in Novel Oncology Biomarkers<\/strong><\/h2>\n\n\n\n

Over 475 articles related to novel cancer biomarkers have been published, since 2019, highlighting the substantial efforts made by industry stakeholders and researchers in cancer biomarkers market. Around 95% of these publications were research articles, followed by review articles, care reports and method articles. In addition, the maximum number of articles focused on cancer biomarkers were filed by Frontiers Media, BioMed Central, MDPI, Impact Journals, Nature Publishing Group UK, John Wiley and Sons, Dove and Elsevier.<\/p>\n\n\n\n

Regional Analysis: North America Holds the Largest Market Share of Cancer Biomarkers Market; Asia Pacific to be the Fastest Growing Market<\/strong><\/h2>\n\n\n\n

Presently, North America and Europe capture more than 65% of the market size of oncology biomarkers. In recent years, owing to the large investment in cancer research and development, North America has witnessed a tremendous increase in the adoption of biomarker testing for oncological disorders. It is worth highlighting that, in the coming years, owing to the anticipated improvement in the establishment of insurance coverage for oncology biomarkers testing in Asia Pacific, this region is likely to grow at a higher CAGR as compared to other regions.<\/p>\n\n\n\n

Future Perspectives and Conclusion<\/strong><\/h2>\n\n\n\n

In conclusion, the healthcare industry has made significant strides in the development of advanced cancer treatment options, including targeted therapies, immunotherapies, and anti-cancer vaccines. However, the high failure rates and drug-related limitations in clinical cancer research highlight the need for a more personalized approach to cancer treatment. Oncology precision medicine<\/a> , which involves the use of molecular markers to make personalized treatment decisions, has emerged as a promising solution.<\/p>\n\n\n\n

Advances in biotechnology have enabled the development of high throughput tools that have led to the establishment of better biomarkers<\/a>  based on genome\/exome profiles. Novel biomarkers, such as tumor mutation burden (TMB), microsatellite instability (MSI) \/ mismatch repair (MMR) deficiency, tumor infiltrating lymphocytes (TILs), Single Nucleotide Variants (SNV), Copy Number Variants (CNV), and others, are being investigated across numerous clinical studies.<\/p>\n\n\n\n

Diagnostics-focused companies have developed or are developing analytical tests for these biomarkers, which are intended to assist physicians in making personalized treatment-related decisions. Big pharmaceutical players have also shown interest in this domain, launching clinical research initiatives to investigate the relevance and applications of multiple novel biomarkers.<\/p>\n\n\n\n

In the future, the cancer biomarkers market is expected to grow, with North America and Europe currently capturing more than 65% of the market size. The anticipated improvement in the establishment of insurance coverage for biomarker testing in Asia Pacific is likely to drive the growth of this region at a higher CAGR as compared to other regions.<\/p>\n\n\n\n

Moreover, the development of novel biomarkers and personalized treatment approaches is a promising area of research in cancer treatment. The growing interest and investment in this field are expected to lead to significant advancements in the diagnosis and treatment of various cancer indications.<\/p>\n\n\n\n

To know more details on the cancer biomarkers market visit here  <\/strong>https:\/\/www.rootsanalysis.com\/reports\/cancer-biomarkers-market\/253.html<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Over the last couple of decades, the healthcare market has witnessed the entry of several advanced and effective treatment options for cancer; these include a variety of targeted therapies, immunotherapies and certain anti-cancer vaccines as well. However, clinical cancer research is still plagued by high failure rates, various drug \/ therapy-related limitations, and treatment-based adverse […]<\/p>\n","protected":false},"author":64,"featured_media":17517,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1560,1],"tags":[1561],"class_list":["post-21524","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-oncology-biomarkers","category-uncategorized","tag-oncology-biomarkers"],"yoast_head":"\nNovel Oncology Biomarkers: Market Insights & Future Outlook<\/title>\n<meta name=\"description\" content=\"Novel oncology biomarkers like TMB, MSI\/MMR deficiency, and TILs are under study in various clinical trials.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.rootsanalysis.com\/blog\/oncology-biomarkers-current-landscape\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novel Oncology Biomarkers: Market Insights & Future Outlook\" \/>\n<meta property=\"og:description\" content=\"Novel oncology biomarkers like TMB, MSI\/MMR deficiency, and TILs are under study in various clinical trials.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.rootsanalysis.com\/blog\/oncology-biomarkers-current-landscape\/\" \/>\n<meta property=\"og:site_name\" content=\"Blog\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/RootsAnalysis\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-31T10:53:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-18T13:10:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2023\/10\/Novel-Biomarkers-and-Rise-of-TMB-Roots.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"300\" \/>\n\t<meta property=\"og:image:height\" content=\"200\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Simran Kaur\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@RootsAnalysis\" \/>\n<meta name=\"twitter:site\" content=\"@RootsAnalysis\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Simran Kaur\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/oncology-biomarkers-current-landscape\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/oncology-biomarkers-current-landscape\\\/\"},\"author\":{\"name\":\"Simran Kaur\",\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/#\\\/schema\\\/person\\\/168b619130a80169be0c615f6118cf4f\"},\"headline\":\"Oncology Biomarkers: Current Landscape, Growth Opportunities and Future Market Outlook\",\"datePublished\":\"2024-07-31T10:53:13+00:00\",\"dateModified\":\"2025-09-18T13:10:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/oncology-biomarkers-current-landscape\\\/\"},\"wordCount\":1149,\"publisher\":{\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/oncology-biomarkers-current-landscape\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/Novel-Biomarkers-and-Rise-of-TMB-Roots.webp\",\"keywords\":[\"oncology biomarkers\"],\"articleSection\":[\"ONCOLOGY BIOMARKERS\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/oncology-biomarkers-current-landscape\\\/\",\"url\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/oncology-biomarkers-current-landscape\\\/\",\"name\":\"Novel Oncology Biomarkers: Market Insights & Future Outlook\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/oncology-biomarkers-current-landscape\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/oncology-biomarkers-current-landscape\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/Novel-Biomarkers-and-Rise-of-TMB-Roots.webp\",\"datePublished\":\"2024-07-31T10:53:13+00:00\",\"dateModified\":\"2025-09-18T13:10:43+00:00\",\"description\":\"Novel oncology biomarkers like TMB, MSI\\\/MMR deficiency, and TILs are under study in various clinical trials.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/oncology-biomarkers-current-landscape\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/oncology-biomarkers-current-landscape\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/oncology-biomarkers-current-landscape\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/Novel-Biomarkers-and-Rise-of-TMB-Roots.webp\",\"contentUrl\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/Novel-Biomarkers-and-Rise-of-TMB-Roots.webp\",\"width\":300,\"height\":200,\"caption\":\"This is a feature image for blog article Cancer Biomakers at Roots Analysis\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/oncology-biomarkers-current-landscape\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Oncology Biomarkers: Current Landscape, Growth Opportunities and Future Market Outlook\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/#website\",\"url\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/\",\"name\":\"Blog\",\"description\":\"Roots Analysis\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/#organization\",\"name\":\"Roots Analysis\",\"url\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/wp-content\\\/uploads\\\/2018\\\/11\\\/Roots-Analysis-High-Resolution-Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/wp-content\\\/uploads\\\/2018\\\/11\\\/Roots-Analysis-High-Resolution-Logo.jpg\",\"width\":205,\"height\":61,\"caption\":\"Roots Analysis\"},\"image\":{\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/RootsAnalysis\\\/\",\"https:\\\/\\\/x.com\\\/RootsAnalysis\",\"https:\\\/\\\/www.instagram.com\\\/rootsanalysis\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/roots-analysis\\\/\",\"https:\\\/\\\/www.pinterest.it\\\/analysis1340\\\/\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UCwZF57vY1lnU0bNLej2zukg\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/#\\\/schema\\\/person\\\/168b619130a80169be0c615f6118cf4f\",\"name\":\"Simran Kaur\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b4ae5484c2f7c17bb89963a27fac737e2a47311ec94a0643677e750b94bb9cf4?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b4ae5484c2f7c17bb89963a27fac737e2a47311ec94a0643677e750b94bb9cf4?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b4ae5484c2f7c17bb89963a27fac737e2a47311ec94a0643677e750b94bb9cf4?s=96&d=mm&r=g\",\"caption\":\"Simran Kaur\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Novel Oncology Biomarkers: Market Insights & Future Outlook","description":"Novel oncology biomarkers like TMB, MSI\/MMR deficiency, and TILs are under study in various clinical trials.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.rootsanalysis.com\/blog\/oncology-biomarkers-current-landscape\/","og_locale":"en_US","og_type":"article","og_title":"Novel Oncology Biomarkers: Market Insights & Future Outlook","og_description":"Novel oncology biomarkers like TMB, MSI\/MMR deficiency, and TILs are under study in various clinical trials.","og_url":"https:\/\/www.rootsanalysis.com\/blog\/oncology-biomarkers-current-landscape\/","og_site_name":"Blog","article_publisher":"https:\/\/www.facebook.com\/RootsAnalysis\/","article_published_time":"2024-07-31T10:53:13+00:00","article_modified_time":"2025-09-18T13:10:43+00:00","og_image":[{"width":300,"height":200,"url":"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2023\/10\/Novel-Biomarkers-and-Rise-of-TMB-Roots.webp","type":"image\/webp"}],"author":"Simran Kaur","twitter_card":"summary_large_image","twitter_creator":"@RootsAnalysis","twitter_site":"@RootsAnalysis","twitter_misc":{"Written by":"Simran Kaur","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.rootsanalysis.com\/blog\/oncology-biomarkers-current-landscape\/#article","isPartOf":{"@id":"https:\/\/www.rootsanalysis.com\/blog\/oncology-biomarkers-current-landscape\/"},"author":{"name":"Simran Kaur","@id":"https:\/\/www.rootsanalysis.com\/blog\/#\/schema\/person\/168b619130a80169be0c615f6118cf4f"},"headline":"Oncology Biomarkers: Current Landscape, Growth Opportunities and Future Market Outlook","datePublished":"2024-07-31T10:53:13+00:00","dateModified":"2025-09-18T13:10:43+00:00","mainEntityOfPage":{"@id":"https:\/\/www.rootsanalysis.com\/blog\/oncology-biomarkers-current-landscape\/"},"wordCount":1149,"publisher":{"@id":"https:\/\/www.rootsanalysis.com\/blog\/#organization"},"image":{"@id":"https:\/\/www.rootsanalysis.com\/blog\/oncology-biomarkers-current-landscape\/#primaryimage"},"thumbnailUrl":"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2023\/10\/Novel-Biomarkers-and-Rise-of-TMB-Roots.webp","keywords":["oncology biomarkers"],"articleSection":["ONCOLOGY BIOMARKERS"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.rootsanalysis.com\/blog\/oncology-biomarkers-current-landscape\/","url":"https:\/\/www.rootsanalysis.com\/blog\/oncology-biomarkers-current-landscape\/","name":"Novel Oncology Biomarkers: Market Insights & Future Outlook","isPartOf":{"@id":"https:\/\/www.rootsanalysis.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.rootsanalysis.com\/blog\/oncology-biomarkers-current-landscape\/#primaryimage"},"image":{"@id":"https:\/\/www.rootsanalysis.com\/blog\/oncology-biomarkers-current-landscape\/#primaryimage"},"thumbnailUrl":"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2023\/10\/Novel-Biomarkers-and-Rise-of-TMB-Roots.webp","datePublished":"2024-07-31T10:53:13+00:00","dateModified":"2025-09-18T13:10:43+00:00","description":"Novel oncology biomarkers like TMB, MSI\/MMR deficiency, and TILs are under study in various clinical trials.","breadcrumb":{"@id":"https:\/\/www.rootsanalysis.com\/blog\/oncology-biomarkers-current-landscape\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.rootsanalysis.com\/blog\/oncology-biomarkers-current-landscape\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.rootsanalysis.com\/blog\/oncology-biomarkers-current-landscape\/#primaryimage","url":"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2023\/10\/Novel-Biomarkers-and-Rise-of-TMB-Roots.webp","contentUrl":"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2023\/10\/Novel-Biomarkers-and-Rise-of-TMB-Roots.webp","width":300,"height":200,"caption":"This is a feature image for blog article Cancer Biomakers at Roots Analysis"},{"@type":"BreadcrumbList","@id":"https:\/\/www.rootsanalysis.com\/blog\/oncology-biomarkers-current-landscape\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.rootsanalysis.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Oncology Biomarkers: Current Landscape, Growth Opportunities and Future Market Outlook"}]},{"@type":"WebSite","@id":"https:\/\/www.rootsanalysis.com\/blog\/#website","url":"https:\/\/www.rootsanalysis.com\/blog\/","name":"Blog","description":"Roots Analysis","publisher":{"@id":"https:\/\/www.rootsanalysis.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.rootsanalysis.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.rootsanalysis.com\/blog\/#organization","name":"Roots Analysis","url":"https:\/\/www.rootsanalysis.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.rootsanalysis.com\/blog\/#\/schema\/logo\/image\/","url":"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2018\/11\/Roots-Analysis-High-Resolution-Logo.jpg","contentUrl":"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2018\/11\/Roots-Analysis-High-Resolution-Logo.jpg","width":205,"height":61,"caption":"Roots Analysis"},"image":{"@id":"https:\/\/www.rootsanalysis.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/RootsAnalysis\/","https:\/\/x.com\/RootsAnalysis","https:\/\/www.instagram.com\/rootsanalysis\/","https:\/\/www.linkedin.com\/company\/roots-analysis\/","https:\/\/www.pinterest.it\/analysis1340\/","https:\/\/www.youtube.com\/channel\/UCwZF57vY1lnU0bNLej2zukg"]},{"@type":"Person","@id":"https:\/\/www.rootsanalysis.com\/blog\/#\/schema\/person\/168b619130a80169be0c615f6118cf4f","name":"Simran Kaur","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/b4ae5484c2f7c17bb89963a27fac737e2a47311ec94a0643677e750b94bb9cf4?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/b4ae5484c2f7c17bb89963a27fac737e2a47311ec94a0643677e750b94bb9cf4?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b4ae5484c2f7c17bb89963a27fac737e2a47311ec94a0643677e750b94bb9cf4?s=96&d=mm&r=g","caption":"Simran Kaur"}}]}},"_links":{"self":[{"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/posts\/21524","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/comments?post=21524"}],"version-history":[{"count":8,"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/posts\/21524\/revisions"}],"predecessor-version":[{"id":22281,"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/posts\/21524\/revisions\/22281"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/media\/17517"}],"wp:attachment":[{"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/media?parent=21524"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/categories?post=21524"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/tags?post=21524"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}